Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Acrivon Therapeutics, Inc. - Common Stock
(NQ:
ACRV
)
9.240
-0.260 (-2.74%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Sep 12, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Acrivon Therapeutics, Inc. - Common Stock
< Previous
1
2
Next >
Acrivon Therapeutics Announces the Appointment of Seasoned Biopharma Executive Charles Baum, M.D., Ph.D., a Recognized Leader in Clinical Precision Oncology, to its Board of Directors
June 22, 2023
Dr. Baum comes with more than 30 years of biopharma industry leadership experience, including at Mirati Therapeutics, Pfizer and Schering-Plough
From
Acrivon Therapeutics, Inc
Via
GlobeNewswire
Acrivon Therapeutics to Present at the Jefferies Healthcare Conference
June 02, 2023
From
Acrivon Therapeutics, Inc
Via
GlobeNewswire
Acrivon Therapeutics Announces FDA Grants Fast Track Designation for Development of ACR-368 in Platinum-Resistant Ovarian Cancer and Endometrial Cancer
May 09, 2023
From
Acrivon Therapeutics, Inc
Via
GlobeNewswire
Acrivon Therapeutics Reports First Quarter 2023 Financial Results and Business Highlights
May 09, 2023
From
Acrivon Therapeutics, Inc
Via
GlobeNewswire
Acrivon Therapeutics to Present at the H.C. Wainwright BioConnect Investor Conference
April 25, 2023
From
Acrivon Therapeutics, Inc
Via
GlobeNewswire
Acrivon Therapeutics to Host Virtual Investor Event on May 1, 2023
April 24, 2023
From
Acrivon Therapeutics, Inc
Via
GlobeNewswire
Acrivon Therapeutics to Present at the Stifel 2023 Targeted Oncology Days Conference
April 18, 2023
From
Acrivon Therapeutics, Inc
Via
GlobeNewswire
Acrivon Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Business Highlights
March 28, 2023
From
Acrivon Therapeutics, Inc
Via
GlobeNewswire
Acrivon Therapeutics to Present at the Oppenheimer 33rd Annual Healthcare Conference
March 06, 2023
From
Acrivon Therapeutics, Inc
Via
GlobeNewswire
Acrivon Therapeutics to Participate on a Panel at Cowen’s 43rd Annual Health Care Conference
February 27, 2023
CEO to participate on ovarian cancer panel and will highlight ACR-368, a DNA Damage Response (DDR) inhibitor in clinical testing for platinum-resistant advanced ovarian cancer and other solid tumors
From
Acrivon Therapeutics, Inc
Via
GlobeNewswire
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.